First National Bank of Omaha Buys New Shares in Boston Scientific Corporation $BSX

First National Bank of Omaha acquired a new stake in shares of Boston Scientific Corporation (NYSE:BSX) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 81,813 shares of the medical equipment provider’s stock, valued at approximately $3,533,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Kelleher Financial Advisors bought a new stake in Boston Scientific in the second quarter worth $25,000. FWL Investment Management LLC bought a new position in shares of Boston Scientific in the second quarter worth approximately $26,000. Swiss RE Ltd. bought a new stake in Boston Scientific during the 4th quarter valued at $26,000. Garton & Associates Financial Advisors LLC purchased a new position in shares of Boston Scientific in the fourth quarter valued at about $26,000. Finally, Clal Insurance Enterprises Holdings Ltd bought a new position in shares of Boston Scientific during the first quarter valued at about $28,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Transactions at Boston Scientific

In related news, Director David C. Habiger purchased 2,100 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The stock was purchased at an average price of $47.59 per share, with a total value of $99,939.00. Following the completion of the purchase, the director owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. The trade was a 13.94% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Michael F. Mahoney bought 186,240 shares of the stock in a transaction on Monday, August 3rd. The stock was purchased at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the acquisition, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have purchased 194,522 shares of company stock valued at $9,385,210. 0.34% of the stock is currently owned by company insiders.

Analyst Ratings Changes

BSX has been the topic of a number of research analyst reports. Wolfe Research downgraded shares of Boston Scientific from an “outperform” rating to a “peer perform” rating in a research report on Friday, May 29th. BTIG Research lowered their price target on shares of Boston Scientific from $65.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, July 29th. Bank of America reduced their price target on Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a report on Monday, May 18th. Daiwa Securities Group cut shares of Boston Scientific from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 29th. Finally, The Goldman Sachs Group set a $71.00 target price on Boston Scientific in a research note on Thursday, May 28th. Twenty-four investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $71.62.

Boston Scientific Trading Down 1.8%

Shares of NYSE BSX opened at $50.51 on Wednesday. The business’s 50 day moving average price is $46.15 and its 200-day moving average price is $58.50. Boston Scientific Corporation has a fifty-two week low of $42.20 and a fifty-two week high of $109.50. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. The company has a market cap of $73.20 billion, a price-to-earnings ratio of 20.45, a PEG ratio of 1.13 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The business had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business’s revenue was up 7.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, sell-side analysts expect that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific announced that its Board of Directors has authorized a share repurchase program on Monday, May 18th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.